HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 297 filers reported holding HAEMONETICS CORP in Q3 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,008,276 | +162.3% | 33,582 | +149.3% | 0.00% | +300.0% |
| Q2 2023 | $1,146,836 | -37.2% | 13,470 | -39.0% | 0.00% | -66.7% |
| Q1 2023 | $1,826,624 | +193.0% | 22,074 | +178.5% | 0.00% | +200.0% |
| Q4 2022 | $623,380 | -100.0% | 7,926 | -54.7% | 0.00% | -50.0% |
| Q3 2022 | $1,295,525,000 | +59.9% | 17,500 | +40.8% | 0.00% | +100.0% |
| Q2 2022 | $810,122,000 | -64.5% | 12,429 | -65.6% | 0.00% | -66.7% |
| Q1 2022 | $2,283,822,000 | -46.0% | 36,125 | -54.7% | 0.00% | -50.0% |
| Q4 2021 | $4,229,781,000 | +522.0% | 79,747 | +727.8% | 0.01% | +500.0% |
| Q3 2021 | $680,064,000 | +48.0% | 9,634 | +39.7% | 0.00% | 0.0% |
| Q2 2021 | $459,549,000 | -93.1% | 6,896 | -88.5% | 0.00% | -90.0% |
| Q1 2021 | $6,631,626,000 | +526.8% | 59,739 | +570.5% | 0.01% | +400.0% |
| Q4 2020 | $1,058,062,000 | -45.9% | 8,910 | -60.2% | 0.00% | -33.3% |
| Q3 2020 | $1,954,574,000 | -79.9% | 22,402 | -79.4% | 0.00% | -82.4% |
| Q2 2020 | $9,726,216,000 | +1016.6% | 108,600 | +1142.6% | 0.02% | +750.0% |
| Q1 2020 | $871,028,000 | -76.8% | 8,740 | -73.3% | 0.00% | -71.4% |
| Q4 2019 | $3,761,481,000 | +195.7% | 32,737 | +224.6% | 0.01% | +250.0% |
| Q3 2019 | $1,272,122,000 | +73.4% | 10,085 | +65.4% | 0.00% | +100.0% |
| Q2 2019 | $733,833,000 | -24.2% | 6,098 | -44.9% | 0.00% | -50.0% |
| Q1 2019 | $968,316,000 | +1003.6% | 11,069 | +1162.1% | 0.00% | – |
| Q4 2018 | $87,744,000 | -87.7% | 877 | -85.9% | 0.00% | -100.0% |
| Q3 2018 | $714,750,000 | -92.5% | 6,238 | -94.1% | 0.00% | -93.8% |
| Q2 2018 | $9,549,844,000 | +649.9% | 106,488 | +511.8% | 0.02% | +700.0% |
| Q1 2018 | $1,273,423,000 | -0.3% | 17,406 | -20.8% | 0.00% | 0.0% |
| Q4 2017 | $1,277,121,000 | +3.1% | 21,989 | -20.3% | 0.00% | -33.3% |
| Q3 2017 | $1,238,547,000 | +74.3% | 27,603 | +53.4% | 0.00% | +50.0% |
| Q2 2017 | $710,662,000 | +59.4% | 17,996 | +63.8% | 0.00% | +100.0% |
| Q1 2017 | $445,743,000 | +0.7% | 10,987 | -0.2% | 0.00% | -50.0% |
| Q4 2016 | $442,562,000 | +44.0% | 11,009 | +29.7% | 0.00% | +100.0% |
| Q3 2016 | $307,350,000 | -36.1% | 8,488 | -48.8% | 0.00% | -50.0% |
| Q2 2016 | $480,741,000 | +70.9% | 16,583 | +106.2% | 0.00% | +100.0% |
| Q1 2016 | $281,344,000 | -29.7% | 8,043 | -35.3% | 0.00% | 0.0% |
| Q4 2015 | $400,486,000 | +9.4% | 12,422 | +9.7% | 0.00% | 0.0% |
| Q3 2015 | $366,056,000 | +90.9% | 11,326 | +144.3% | 0.00% | 0.0% |
| Q2 2015 | $191,786,000 | +244.0% | 4,637 | +273.7% | 0.00% | – |
| Q1 2015 | $55,746,000 | -48.7% | 1,241 | -60.1% | 0.00% | – |
| Q3 2014 | $108,636,000 | +2889.4% | 3,111 | +2920.4% | 0.00% | – |
| Q2 2014 | $3,634,000 | +185.0% | 103 | +145.2% | 0.00% | – |
| Q1 2014 | $1,275,000 | -95.4% | 42 | -93.7% | 0.00% | – |
| Q4 2013 | $27,890,000 | -95.0% | 662 | -95.3% | 0.00% | – |
| Q3 2013 | $561,231,000 | -23.8% | 14,073 | -20.9% | 0.00% | -100.0% |
| Q2 2013 | $736,113,000 | – | 17,802 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |